Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
About Us
Conferences
Videos
Webinars
Media & Press
Top Story
Prostate Cancer
In pilot study, liquid biopsy test differentiates between localized and metastatic cancer to inform tailored treatment
Cedars-Sinai Cancer researchers are developing a microfluidic device with a nanosurface as part of a blood test to inform treatment decisions.
Featured
Financial Results
Roche reports flat diagnostics revenue growth for 2022
Mergers & Acquisitions
Sherlock Biosciences acquires Sense Biodetection to drive CRISPR-based test adoption
Latest News
Policy forum reviews NIH response to the COVID-19 pandemic
February 3, 2023
Siemens Healthineers, Unilabs ink 200-million euro agreement
February 2, 2023
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
February 2, 2023
Hologic fiscal Q1 diagnostics revenues drop 27% on lower demand for COVID testing
February 2, 2023
Business Insights
Financial Results
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
Financial Results
Hologic fiscal Q1 diagnostics revenues drop 27% on lower demand for COVID testing
Financial Results
Roche reports flat diagnostics revenue growth for 2022
Collaboration
Genetic Technologies, Qiagen forming strategic alliance
Diagnostic Technologies
Collaboration
Siemens Healthineers, Unilabs ink 200-million euro agreement
Pathology and AI
3D spatial maps characterize biology enabling tumor growth: NIH director
Collaboration
Genetic Technologies, Qiagen forming strategic alliance
Artificial Intelligence
Guardant NSCLC biomarker test to incorporate Lunit’s AI-based scoring algorithm
Diseases
Financial Results
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
Financial Results
Hologic fiscal Q1 diagnostics revenues drop 27% on lower demand for COVID testing
Sepsis
Sepsis increases heart failure, rehospitalization risks following hospital discharge
Cancer
Study suggests immune response to anticancer checkpoint inhibitors unaffected by COVID-19 vaccination
More from LabPulse.com
Sepsis increases heart failure, rehospitalization risks following hospital discharge
Hospital patients who initially had or developed sepsis were at higher risk for heart failure, rehospitalization, or death within 12 years than patients without sepsis.
February 1, 2023
AstraZeneca, Capitainer to develop biomarker protocols using at-home patient sampling device
Capitainer's quantitative self-sampling product automatically separates cells from whole blood using a finger stick that can be done in a patient's home, potentially expanding access to individuals who would participate in clinical trials.
February 1, 2023
Study suggests immune response to anticancer checkpoint inhibitors unaffected by COVID-19 vaccination
Using an IgG ELISA kit and ELISPOT assay, the collaborators quantified immune responses in 41 people who were taking anti-PD-1/L1 checkpoint inhibitors to treat a range of cancers.
February 1, 2023
3D spatial maps characterize biology enabling tumor growth: NIH director
In an NIH-sponsored study, researchers used cyclic immunofluorescence to obtain many rounds of highly detailed molecular imaging on each tissue sample and provided molecular data, cell by cell.
January 31, 2023
Genetic Technologies, Qiagen forming strategic alliance
Genetic Technologies said the alliance is expected to support the enhancement of its capabilities through software, hardware, consumable, and other technical solutions.
February 1, 2023
Beckman Coulter, MeMed collaborate to expand adoption of host immune response diagnostic test
MeMed developed its BV test to address the management of patients with acute infection in different clinical settings, including emergency departments, and distinguish between bacterial and viral infections early in the diagnostic process.
January 31, 2023
Most Popular
Researchers find hidden bacteria that pose antimicrobial resistance risk to hospital patients
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
SD Biosensor, SJL Partners complete acquisition of Meridian Bioscience
OIG report outlines challenges with CDC-supported COVID-19 vaccination programs
Duke University developing blood test to detect osteoarthritis progression in the knee
Roche reports flat diagnostics revenue growth for 2022
More from LabPulse.com
Guardant NSCLC biomarker test to incorporate Lunit’s AI-based scoring algorithm
The integrated Lunit Scope PD-L1 algorithm will augment the TissueNext test’s detection of the PD-L1 biomarker in tissue samples using an AI-based scoring system.
February 1, 2023
Jana Care, Roche to develop blood-testing platform for chronic kidney and heart disease
The platform would enable patients to self-administer critical blood tests at home, and allow clinicians to review the test results remotely.
January 31, 2023
Duke University developing blood test to detect osteoarthritis progression in the knee
A new blood test may identify osteoarthritis progression in the knee more accurately than other methods, potentially advancing research and new therapies.
January 30, 2023
SD Biosensor, SJL Partners complete acquisition of Meridian Bioscience
The acquisition was agreed upon in July 2022 as an all-cash transaction valued at approximately $1.53 billion.
February 1, 2023
French point-of-care testing firm Biosynex to acquire Chembio Diagnostics for $17.2M
Each diagnostic company specializes in the development, manufacturing, and marketing of point-of-care diagnostic tests for the professional and at-home markets.
February 1, 2023
California sisters plead guilty in $7.5M Medicare fraud involving phlebotomy services
They billed Medicare for medical services that were not reimbursable and overstated mileage for their traveling phlebotomists, according to the U.S. Attorney's Office for the Eastern District of California.
January 27, 2023
